Molecular Cloning and Characterization of a Human beta -Gal-3'-sulfotransferase That Acts on Both Type 1 and Type 2 (Galbeta 1-3/1-4GlcNAc-R) Oligosaccharides*

Koichi HonkeDagger §, Masayuki Tsuda, Souichi KoyotaDagger , Yoshinao Wada, Naoko Iida-Tanaka||, Ineo Ishizuka||, Jun Nakayama**, and Naoyuki TaniguchiDagger

From the Dagger  Department of Biochemistry, Osaka University Medical School, Suita, Osaka 565-0871, the  Department of Molecular Medicine, Research Institute, Osaka Medical Center for Maternal and Child Health, Izumi, Osaka 594-1101, the || Department of Biochemistry, Teikyo University School of Medicine, Tokyo 173-8605, and the ** Institute of Organ Transplants, Reconstructive Medicine and Tissue Engineering, Shinshu University Graduate School of Medicine, Matsumoto 390-8621, Japan

Received for publication, June 28, 2000, and in revised form, October 10, 2000



    ABSTRACT
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

A novel sulfotransferase gene (designated GP3ST) was identified on human chromosome 2q37.3 based on its similarity to the cerebroside 3'-sulfotransferase (CST) cDNA (Honke, K., Tsuda, M., Hirahara, Y., Ishii, A., Makita, A., and Wada, Y. (1997) J. Biol. Chem. 272, 4864-4868). A full-length cDNA was obtained by reverse transcription-polymerase chain reaction and 5'- and 3'-rapid amplification of cDNA ends analyses of human colon mRNA. The isolated cDNA clone predicts that the protein is a type II transmembrane protein composed of 398 amino acid residues. The amino acid sequence indicates 33% identity to the human CST sequence. A recombinant protein that is expressed in COS-1 cells showed no CST activity, but did show sulfotransferase activities toward oligosaccharides containing nonreducing beta -galactosides such as N-acetyllactosamine, lactose, lacto-N-tetraose (Lc4), lacto-N-neotetraose (nLc4), and Galbeta 1-3GalNAcalpha -benzyl (O-glycan core 1 oligosaccharide). To characterize the cloned sulfotransferase, a sulfotransferase assay method was developed that uses pyridylaminated (PA) Lc4 and nLc4 as enzyme substrates. The enzyme product using PA-Lc4 as an acceptor was identified as HSO3-3Galbeta 1-3GlcNAcbeta 1-3Galbeta 1-4Glc-PA by two-dimensional 1H NMR. Kinetics studies suggested that GP3ST is able to act on both type 1 (Galbeta 1-3GlcNAc-R) and type 2 (Galbeta 1-4GlcNAc-R) chains with a similar efficiency. In situ hybridization demonstrated that the GP3ST gene is expressed in epithelial cells lining the lower to middle layer of the crypts in colonic mucosa, hepatocytes surrounding the central vein of the liver, extravillous cytotrophoblasts in the basal plate and septum of the placenta, renal tubules of the kidney, and neuronal cells of the cerebral cortex. The results of this study indicate the existence of a novel beta -Gal-3'-sulfotransferase gene family.



    INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Sulfated glycoconjugates, whose sulfate groups are biologically relevant, occur in a wide range of biological compounds (reviewed in Ref. 1), including glycoproteins, proteoglycans, glycolipids, and polysaccharides. The enzymes responsible for the sulfation of these compounds, sulfotransferases, utilize in common the sulfate donor 5'-phosphoadenosine 3'-phosphosulfate (PAPS).1

We recently reported on the purification of the glycolipid 3-sulfotransferase (cerebroside sulfotransferase (CST); galactosylceramide sulfotransferase, EC 2.8.2.11) to homogeneity from human renal cancer cells (2) and the cloning of the human CST cDNA on the basis of the amino acid sequence of the purified enzyme (3). The deduced amino acid sequence shows no overall homology to other sulfotransferases, except for the PAPS-binding motifs, suggesting that CST has a different evolutionary origin (3).

Carbohydrate structures with 3'-sulfo-beta -Gal linkages have been found in both N-glycans (4, 5) and O-glycans (6-13) of glycoproteins, and the beta -Gal-3'-sulfotransferase activities responsible for the synthesis of these glycoproteins have been demonstrated (4, 13-16). The beta -Gal-3'-sulfotransferase synthesizing O-glycans has been demonstrated to be different from CST (13). Thus far, of the sulfotransferases that act on glycoproteins, the molecular cloning of Gal-6'-sulfotransferase and GlcNAc-6-sulfotransferase has been accomplished (17-20). However, no beta -Gal-3'-sulfotransferase genes responsible for the biosynthesis of 3'-sulfo-beta -Gal linkages in glycoproteins have been cloned. The fact that CST transfers a sulfate group to C-3 of the nonreducing terminal beta -galactoside in glycolipids prompted us to undertake a search for a novel beta -Gal-3'-sulfotransferase gene using CST cDNA sequence as a probe.


    EXPERIMENTAL PROCEDURES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Materials-- [35S]PAPS (72.5 GBq/mmol) was purchased from PerkinElmer Life Sciences. Unlabeled PAPS, lacto-N-fucopentaose I (Fucalpha 1-2Galbeta 1-3GlcNAcbeta 1-3Galbeta 1-4Glc), lacto-N-fucopentaose II (Galbeta 1-3(Fucalpha 1-4)GlcNAcbeta 1-3Galbeta 1-4Glc), lacto-N-fucopentaose III (Galbeta 1-4(Fucalpha 1-3)GlcNAcbeta 1-3Galbeta 1-4Glc), N-acetyllactosamine, GalNAcalpha -benzyl, Galbeta 1-3GalNAcalpha -benzyl, Galbeta 1-4Gal, Galalpha 1-4Gal, and methyl-beta -Gal were from Sigma. Lacto-N-tetraose (Galbeta 1-3GlcNAcbeta 1-3Galbeta 1-4Glc; Lc4) and lacto-N-neotetraose (Galbeta 1-4GlcNAcbeta 1-3Galbeta 1-4Glc; nLc4) were purchased from Seikagaku Kogyo (Tokyo, Japan). Methyl-alpha -Gal and lactose were from Nacalai Tesque (Kyoto, Japan). Galactosylceramide and lactosylceramide were prepared in our laboratory as described previously (2). PA-Lc4 and PA-nLc4 were synthesized by pyridylamination of lacto-N-tetraose and lacto-N-neotetraose, respectively, using a GlycoTAG reagent kit (Takara, Shiga, Japan) with an automated pyridylamination apparatus (GlycoTAG, Takara).

Cloning of Human GP3ST cDNA-- One microgram of total RNA isolated from various human tissues (OriGene Technologies, Rockville, MD) was reverse-transcribed with random hexamers and then subjected to PCR. PCR was carried out using Taq DNA polymerase and two pairs of primers: CF2 (5'-TCACCAACATCATGTTC-3', corresponding to human GP3ST cDNA nucleotides 284-300 in Fig. 1A) and CR2 (5'-TGAGGCAGGTTGAACCT-3', corresponding to nucleotides 490-506); and CF1 (5'-CCAACGACACCTTCTAC-3', corresponding to nucleotides 524-540) and CR1 (5'-GGAACGGGATGTTCTTG-3', corresponding to nucleotides 1302-1318), which are located in the putative exons of the CST-like candidate gene in the CEB1 cosmid (GenBankTM/EBI accession number AF048727). The PCR products were electrophoresed on 1.5% agarose gel. DNA fragments with the expected sizes of 223 and 795 base pairs, respectively, were excised and subcloned into pT7 Blue(R) (Novagen, Madison, WI) and sequenced as described below. The determined sequences were identical to those in the CEB1 cosmid, and the cloned DNA fragments were designated LIKE-C1 and LIKE-C2.

The 5'-end of human GP3ST cDNA was cloned by the rapid amplification of cDNA ends (RACE) (21) using a 5'-RACE system kit (Life Technologies, Inc.). According to the manufacturer's recommended protocol, 1 µg of total RNA from human colon (OriGene Technologies) was reverse-transcribed with the GP3ST gene-specific antisense primer CR2. The first strand cDNA was tailed at the 3'-end by terminal deoxynucleotidyltransferase with dATP and then subjected to PCR. PCR was accomplished using Taq DNA polymerase, a 3'-RACE adapter primer (5'-GGCCACGCGTCGACTAGTACTTTTTTTTTTTTTTTTT-3'), and the GP3ST gene-specific antisense primer CR3 (5'-GACCCCACGCCTTCCACGTA-3', corresponding to nucleotides 436-455). The PCR product was electrophoresed on 1.5% agarose gel, and the DNA was transferred to a nylon membrane (Roche Molecular Biochemicals, Tokyo) and hybridized with a digoxigenin-labeled DNA probe synthesized using LIKE-C1 as a template. Southern hybridization was carried out at 42 °C overnight in hybridization buffer containing 50% formamide, 5× SSC, 2% blocking reagent (Roche Molecular Biochemicals), 0.1% N-lauroylsarcosine, and 0.02% SDS. Positive bands were cut out, subcloned into pT7 Blue(R), and sequenced.

The 3'-end of human GP3ST cDNA was cloned using a 3'-RACE system kit (Life Technologies, Inc.) in a similar manner. According to the manufacturer's protocol, 1 µg of human colon total RNA was reverse-transcribed with the 3'-RACE adapter primer and subsequently subjected to PCR. PCR was performed using Taq DNA polymerase, the abridged universal amplification primer (5'-GGCCACGCGTCGACTAGTAC-3'), and the GP3ST gene-specific sense primer CF5 (5'-TCAAGAACCACACGCAGATC-3', corresponding to nucleotides 1115-1134). The PCR product was electrophoresed on 1.5% agarose gel and subjected to Southern blotting as described above, except that the hybridization probe was synthesized using LIKE-C2 as a template.

DNA Sequencing-- The subcloned DNAs were sequenced by the dideoxy chain termination method using a Dye Terminator cycle sequencing kit (PerkinElmer Life Sciences) with a DNA sequencer (Applied Biosystems Model 377).

Overexpression of Human GP3ST in COS-1 Cells and Sulfotransferase Assay-- To obtain a GP3ST cDNA clone that contained the entire open reading frame, RT-PCR was accomplished using total RNA from human colon as a template. PCR was performed using Taq DNA polymerase and a set of primers (CF3, 5'-CCAGAGGCCAAGATGATG-3', corresponding to nucleotides 121-138 in Fig. 1A); and CR6, 5'-GGAGAGAGGAGCTGGTGT-3', corresponding to nucleotides 1362-1379). The PCR product with the expected size of 1259 base pairs was subcloned into pT7 Blue(R) and sequenced as described above. The obtained clone was digested with EcoRI and SalI, and the GP3ST open reading frame fragment was inserted into the EcoRI and SalI sites of pSVK3 (Amersham Pharmacia Biotech), yielding pSV-GP3ST. COS-1 cells (1 × 106) that had been pre-cultured for 1 day in a 10-cm diameter dish were transfected with 10 µg of pSV-GP3ST and 30 µl of LipofectAMINE (Life Technologies, Inc.). After 72 h, the cells were washed twice with 10 ml of cold phosphate-buffered saline, harvested with 1 ml of phosphate-buffered saline using a silicon scraper, centrifuged at 1500 rpm for 2 min, sonicated in 0.3 ml of ice-cold Tris-buffered saline containing 0.1% Triton X-100, and assayed for sulfotransferase activity according to the method for CST activity (2). When oligosaccharides were used as acceptor substrates, water was employed as the eluant in DEAE A25 column chromatography as a substitute for the organic solvent.

GP3ST Activity Assay Using PA-Lc4 and PA-nLc4-- The standard incubation mixture contained the following components in a total volume of 25 µl: 100 mM MES (pH 6.2), 10 mM MnCl2, 1% Lubrol PX, 1 mM PAPS, 0.2 mM PA-Lc4 or PA-nLc4, and 7.5 µl of enzyme source. After incubation at 37 °C for 2 h, the reaction was terminated by boiling for 2 min. The sample was centrifuged at 15,000 rpm for 5 min, and 20 µl of the supernatant was transferred to a new tube, followed by dilution with 180 µl of water; and 50 µl of the diluted solution was injected onto a TSKgel SuperQ-5PW column (7.5 × 75 mm; Tosoh) equipped with a Shimadzu LC-VP HPLC system. Elution was performed with a linear gradient of 0-0.2 M ammonium acetate (pH 9.0) and monitored with a fluorescence spectrophotometer (excitation, 320 nm; and emission, 400 nm).

1H NMR Analysis of the Reaction Product-- For preparation of the NMR sample, a large-scale GP3ST reaction was carried out using PA-Lc4 as a substrate, and the reaction product was isolated by anion-exchange chromatography as described above. The eluate of the anion-exchange chromatography was then directly injected onto a TSKgel ODS-80TM column (4.6 × 75 mm; Tosoh). Elution was carried out at 55 °C with 20 mM ammonium acetate and 0.01% 1-butanol (pH 4.0) at a flow rate of 1.0 ml/min and monitored as described above. A single peak was detected. The effluent corresponding to the peak was collected and dried. Approximately 17 nmol of the reaction product, as evaluated by fluorescence intensity, was deuterium-exchanged; dissolved in 0.1 ml of D2O; and subjected to 1H NMR analysis as described previously (22, 23), except for the use of microtubes (Shigemi, Tokyo). The 1H signals of the pyridylaminated oligosaccharides were assigned based on the 1H-1H DQF-COSY, two-dimensional HOHAHA, and two-dimensional ROESY experiments in a Joel GX-400 spectrometer at 30 °C. In the case of the DQF-COSY and two-dimensional HOHAHA experiments, the data matrices of 256 (t1) × 4096 (t2) points, acquired with a spectral width of 2000 Hz, were zero-filled to 1048 × 4096 data points. The mixing time of the two-dimensional HOHAHA was set at 100 ms, and the two-dimensional ROESY spectrum was acquired with a 200-ms spin-lock period with a spectral width of 5 kHz.

Northern Blot Analysis-- Samples containing 20 µg of total RNAs from human brain, heart, skeletal muscle, kidney, stomach, small intestine, colon, lung, liver, and testis (OriGene Technologies) were denatured in 50% (v/v) formamide, 6% (v/v) formaldehyde, and 20 mM MOPS (pH 7.0) at 65 °C; electrophoresed on 1% agarose gel containing 6% formaldehyde; and then transferred to a nylon membrane. The membrane was hybridized with a digoxigenin-labeled (-)-strand RNA probe made from human GP3ST cDNA.

In Situ Hybridization of GP3ST Transcripts-- To detect GP3ST transcripts in normal human tissues, in situ hybridization was carried out using an RNA probes with nonradioactive labeling as described previously (24). GP3ST gene-specific nucleotide sequence (nucleotides 720-861 in Fig. 1A) was amplified by PCR using a 5'-primer (5'-CCCAAGCTTCGGCTTCGACCCCAA-3') and a 3'-primer (5'-CGGAATTCCAGCGCAGCCGGCGC-3') (HindIII and EcoRI sites are underlined). This amplified DNA fragment was cloned into the HindIII and EcoRI sites of pGEM-3Zf (+) (Promega), and the resultant vector was used for construction of the RNA probe. A digoxigenin-labeled antisense RNA probe was obtained using a HindIII-cut template and T7 RNA polymerase with a DIG RNA labeling mixture (Roche Molecular Biochemicals). Similarly, a sense probe was prepared for negative control experiments using an EcoRI-cut template and SP6 RNA polymerase with the DIG RNA labeling mixture.

Paraffin blocks of normal human tissues, including colon, liver, placenta, kidney, and brain, fixed for 24 h in 20% buffered Formalin (pH 7.4) were selected from the pathology file of the Central Clinical Laboratories of the Shinshu University Hospital (Matsumoto, Japan). The deparaffinized tissue sections were immersed in 0.2 M HCl for 20 min and then digested with 100 µg/ml proteinase K at 37 °C for 20 min, followed by post-fixation with 4% paraformaldehyde. These slides were rinsed with 2 mg/ml glycine, acetylated for 10 min in 0.25% acetic anhydride in 0.1 M triethanolamine (pH 8.0), and then defatted with chloroform and air-dried. After prehybridization with 50% deionized formamide and 2× SSC for 1 h at 45 °C, these slides were hybridized with 0.5 mg/ml antisense or sense probe in 50% deionized formamide, 2.5 mM EDTA (pH 8.0), 300 mM NaCl, 1× Denhardt's solution, 10% dextran sulfate, and 1 mg/ml brewers' yeast tRNA at 45 °C for 48 h.

After hybridization, the slides were washed with 50% formamide and 2× SSC for 1 h at 45 °C and digested with 10 mg/ml RNase A at 37 °C for 30 min. After sequential washing with 2× SSC and 50% formamide at 45 °C for 1 h and 1× SSC and 50% formamide at 45 °C for 1 h, the sections were subjected to immunohistochemistry for detection of the hybridized probes using an alkaline phosphatase-conjugated anti-digoxigenin antibody (Roche Molecular Biochemicals). The alkaline phosphatase reaction was visualized with 5-bromo-4-chloro-3-indolyl phosphate and nitro blue tetrazolium in the presence of levamisole and 10% polyvinyl alcohol. A control study using the sense probe showed no specific reactivity.


    RESULTS
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

cDNA Cloning and the Predicted Protein Sequences of a Novel Sulfotransferase-- When the GenBankTM/EMBL/DDBJ DNA Data Bank was searched for a sequence homologous to the coding region of the human CST gene (3), a cosmid clone containing the minisatellite CEB1 (GenBankTM/EBI accession number AF048727), located on human chromosome 2q37.3, included a significantly similar sequence (25). The CEB1 cosmid includes two exons with open reading frames that together cover 1076 base pairs of the human CST mRNA (25). To investigate the issue of whether the CEB1 candidate gene actually encodes a functional sulfotransferase, we elected to clone its cDNA from human tissues. First, the cDNA fragments LIKE-C1 (nucleotides 284-506 in Fig. 1A) and LIKE-C2 (nucleotides 524-540), which were found in the putative exons of the CEB1 candidate gene, were obtained by RT-PCR using total RNAs from various human tissues. Since the RT-PCR product was strongly detected in the colon (Fig. 5), we employed human colon as a source of mRNA for subsequent cDNA cloning. The 5'- and 3'-ends of the cDNA of the sulfotransferase candidate were obtained by RACE analyses as described under "Experimental Procedures."



View larger version (61K):
[in this window]
[in a new window]
 
Fig. 1.   cDNA and deduced amino acid sequences of human GP3ST. A, the predicted amino acid sequence is indicated by the single-letter amino acid code below the nucleotide sequence. The putative transmembrane portion is double-underlined. The potential N-glycosylation site is indicated by an asterisk. The presumed PAPS-binding sites are boxed. B, shown is a comparison of the amino acid sequences of human GP3ST and human CST (hCST) (3). Asterisks below the sequences show identical residues.

Fig. 1A shows the DNA and deduced amino acid sequences of the cloned cDNA (termed GP3ST). The deduced protein is a type II membrane protein composed of 398 amino acids with a molecular mass of 46,092 Da and has six potential N-glycosylation sites. Its sequence exhibits 33% identity to the human CST sequence (Fig. 1B) and contains PAPS-binding motifs (26), suggesting that the cDNA encodes a sulfotransferase.

Substrate Specificity of GP3ST-- To investigate the issue of whether the isolated cDNA encodes a functional sulfotransferase and, if so, on what substrates the sulfotransferase acts, the cloned cDNA was inserted into a mammalian expression vector, pSVK3 (pSV-GP3ST) and overexpressed in COS-1 cells. We performed a substrate specificity experiment using [35S]PAPS as the sulfate donor, various carbohydrate compounds as acceptors, and cellular lysates of pSV-GP3ST-introduced COS-1 cells as an enzyme source (Table I). A recombinant protein expressed in COS-1 cells showed no CST activity, but did show significant sulfotransferase activities toward oligosaccharides containing nonreducing beta -galactosides such as N-acetyllactosamine, lactose, Lc4, nLc4, and Galbeta 1-3GalNAcalpha -benzyl (O-glycoside core 1 oligosaccharide). On the other hand, the COS-1 cells transfected with pSV-CST (3) or with pSVK3 alone did not show sulfotransferase activity toward any of the oligosaccharides examined (data not shown).


                              
View this table:
[in this window]
[in a new window]
 
Table I
Substrate specificity of GP3ST

Sulfotransferase Assay Using PA-Lc4 or PA-nLc4 as an Acceptor-- To further characterize the cloned sulfotransferase, we developed a novel sulfotransferase assay system using pyridylaminated oligosaccharides as acceptors. This system was originally developed for use in the structural analysis of oligosaccharides (27) and was later applied to glycosyltransferase assays (28). To separate the acidic products from the neutral substrates, anion-exchange chromatography was employed. A typical elution pattern of the reaction products when PA-Lc4 or PA-nLc4 was used as an acceptor is shown in Fig. 2. The arrows indicate the elution positions of the products. When COS-1 cell lysates transfected with pSV-GP3ST were used as an enzyme source, a robust peak was detected at the positions indicated by the arrows (Fig. 2, b and d), whereas COS-1 cells transfected with the pSVK3 vector alone showed no significant peak at the indicated positions (Fig. 2, a and c). The yield of GP3ST products was increased relative to incubation time (over a period of 2 h) in a linear fashion, as well as at enzyme concentrations up to 1 mg/ml (data not shown).



View larger version (11K):
[in this window]
[in a new window]
 
Fig. 2.   Typical elution profile of the reaction mixture upon anion-exchange chromatography. A reaction mixture, using PA-Lc4 (a and b) or PA-nLc4 (c and d) as a substrate and COS-1 cell lysates transfected with the pSVK3 vector (a and c) or pSV-GP3ST (b and d) as an enzyme source, was applied to a TSKgel SuperQ-5PW column (7.5 × 75 mm) and eluted with a linear gradient of 0-0.2 M ammonium acetate (pH 9.0). Fluorescence was detected at excitation and emission wavelengths of 320 and 400 nm, respectively. The arrows indicate the elution positions of the products.

Identification of the Reaction Product-- To investigate the position where the sulfate group was transferred, a 1H NMR analysis of the enzyme product was performed. For this, a large-scale reaction was performed using PA-Lc4 as a donor, and the product was isolated by sequential HPLC with anion-exchange chromatography and C18 reverse-phase chromatography as described under "Experimental Procedures."

H1-H4 of the Gal residues in PA-Lc4 and the sulfation product (PA-Lc4-S) were assigned by DQF-COSY and two-dimensional HOHAHA. As shown in Fig. 3, the H2-H4 signals of the terminal Gal (IV) residue in PA-Lc4-S were shifted to the lower field by 0.14, 0.67, and 0.38 ppm, respectively, indicating unequivocally that the hydroxyl group at C-3 was esterified by a sulfate. On the other hand, the signals of the internal Gal (II) residue in PA-Lc4-S remained unchanged relative to those in PA-Lc4. To investigate whether or not C-6 was sulfated, the H5 protons were assigned from the two-dimensional ROESY spectra in which the cross-peak between H1 and H5 was observed. The difference in chemical shift of the H5 proton in Gal (IV) was 0.06 ppm (Table II), which is typical for the sulfation at C-3 of the terminal residue (22, 29). The additional downfield shift by ~0.2 ppm, which should result from the sulfation at C-6 (22, 30), was not observed. These results clearly show that GP3ST is a beta -Gal-3'-sulfotransferase that transfers a sulfate group to C-3 of the nonreducing beta -galactosyl residue.



View larger version (14K):
[in this window]
[in a new window]
 
Fig. 3.   Proton NMR spectra of the substrate and the sulfation product. Shown are cross-sections from the two-dimensional HOHAHA spectra through the H1 protons in the terminal Gal (IV) residue in PA-Lc4 (A) and PA-Lc4-S (B).


                              
View this table:
[in this window]
[in a new window]
 
Table II
Chemical shift of the galactosyl protons in PA-Lc4 and the enzyme product (PA-Lc4-S)

Some Properties of GP3ST-- The optimal pH was found to be between 6.0 and 6.5 (Fig. 4) when a MES buffer was used. The effect of divalent cations on GP3ST activity is summarized in Table III. GP3ST essentially has no requirement for divalent cations; and in fact, Cu2+ and Zn2+ strongly inhibited the sulfotransferase activity. The Km values for PA-Lc4, PA-nLc4, and PAPS were found to be 220, 480, and 240 µM, respectively (Table IV). Although the Km value for PA-nLc4 was higher than that for PA-Lc4, the Vmax for PA-nLc4 was higher than that for PA-Lc4, and Vmax/Km values were nearly equal for PA-Lc4 and PA-nLc4, suggesting that GP3ST is able to act on both type 1 and type 2 chains with a similar efficiency.



View larger version (13K):
[in this window]
[in a new window]
 
Fig. 4.   Effect of pH on GP3ST activity. Incubations were carried out at the indicated pH values under standard assay conditions using PA-Lc4 as a substrate in the following buffers: MES (black-square), triethanolamine (), and Tris (black-triangle).


                              
View this table:
[in this window]
[in a new window]
 
Table III
Metal requirements of GP3ST


                              
View this table:
[in this window]
[in a new window]
 
Table IV
Kinetics studies of GP3ST
Kinetics studies were done using the same COS-1 cell lysates that had been transfected with pSV-GP3ST. Studies of PA-Lc4 and PA-nLc4 were carried out in the presence of 1 mM PAPS. A kinetics study for PAPS was performed in the presence of 0.2 mM PA-Lc4.

Tissue-specific Expression of the GP3ST Gene-- Northern blot and RT-PCR analyses using total RNAs from various human tissues consistently showed that GP3ST is ubiquitously transcribed (Fig. 5). Among the examined organs, GP3ST mRNA was found to be highly expressed in heart, stomach, colon, liver, and spleen.



View larger version (59K):
[in this window]
[in a new window]
 
Fig. 5.   Expression of the GP3ST gene in various human tissues. a, Northern blotting. First, 20 µg of total RNA from the indicated organs was electrophoresed, blotted, and hybridized with a digoxigenin-labeled (-)-strand RNA probe made from the full-length human GP3ST cDNA. Lane 1, brain; lane 2, heart; lane 3, skeletal muscle; lane 4, kidney; lane 5, stomach; lane 6, small intestine; lane 7, colon; lane 8, liver; lane 9, testis; lane 10, lung; lane 11, spleen; lane 12, placenta. The sizes of the molecular markers are indicated on the right. b, RT-PCR analysis. Next, 1 µg of total RNA from the indicated organs was reverse-transcribed with a random primer. The resulting cDNA was amplified by PCR using a set of GP3ST primers: CF2 (nucleotides 284-300 in Fig. 1A) and CR2 (nucleotides 490-506). The PCR product was electrophoresed, blotted, and hybridized with a digoxigenin-labeled DNA probe synthesized using the GP3ST cDNA as a template. The observed PCR products showed the predicted size of 223 bases. Lane 1, brain; lane 2, heart; lane 3, skeletal muscle; lane 4, kidney; lane 5, stomach; lane 6, small intestine; lane 7, colon; lane 8, lung; lane 9, liver; lane 10, spleen; lane 11, testis; lane 12, placenta.

Expression of GP3ST Transcripts in Normal Human Tissues-- Since the Northern blot analysis revealed that GP3ST is ubiquitously transcribed, we performed in situ hybridization using an RNA probe specific for GP3ST to determine the cell types that actually express GP3ST transcripts (Fig. 6). Among the various human tissues examined, a specific signal for GP3ST was detected in epithelial cells lining the lower to middle layer of the crypts in colonic mucosa, hepatocytes surrounding the central vein of the liver, extravillous cytotrophoblasts in the basal plate and septum of the placenta, renal tubules of the kidney, and neuronal cells of the cerebral cortex.



View larger version (83K):
[in this window]
[in a new window]
 
Fig. 6.   Expression of human GP3ST transcripts in various human tissues. GP3ST mRNA was detected in epithelial cells located in the lower to middle layer of colonic mucosa (a and f), hepatocytes surrounding the central vein of the liver (b and g), extravillous cytotrophoblasts in the placental septum (c and h), renal tubules of the kidney (d and i), and neuronal cells of the cerebral cortex (e and j). In situ hybridization for GP3ST was carried out using the antisense probe (a-e) and the sense probe as a control (f-j). Bars = 100 µ m.



    DISCUSSION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

We report herein the identification of a novel functional sulfotransferase gene (named GP3ST) based on the similarity of its DNA sequence to that of the CST gene (3). The primary structure of GP3ST showed an overall similarity to that of CST with 33% identity. GP3ST catalyzes the transfer of a sulfate group to C-3 of the nonreducing beta -galactoside in oligosaccharides such as CST. The similarities of structure and function between CST and GP3ST argue that they are members of the beta -Gal-3'-sulfotransferase family. Similarly, several isoforms of this carbohydrate sulfotransferase have been found, e.g. heparan-sulfate N-deacetylase/N-sulfotransferase (31-33), heparan-sulfate glucosaminyl-3-O-sulfotransferase (34, 35), heparan-sulfate 6-O-sulfotransferase (36), chondroitin-sulfate/keratan-sulfate 6-O-sulfotransferase (17, 37), and GlcNAc-6-sulfotransferase (18-20). The distinct regulation of gene expression and the different substrate specificities of these isoforms may give rise to the specificity and diversity of sulfated glycans that are often found in a particular cell type.

CST acts on various nonreducing terminal beta -galactosides in glycolipids such as galactosylceramide, lactosylceramide, galactosyl-1-alkyl-2-acyl-sn-glycerol, and galactosyldiacylglycerol, but it does not act on oligosaccharides that are not associated with lipid (Ref. 2 and this study), suggesting that CST recognizes the nonreducing beta -galactoside of an oligosaccharide chain attached to a lipid moiety. On the other hand, GP3ST acts only on the nonreducing terminal beta -galactoside of an oligosaccharide without lipid, suggesting that this enzyme is involved in the biosynthesis of sulfated glycoproteins. The substrate specificity of GP3ST is similar to that of the mucin 3'-sulfotransferase activity in rat colonic mucosa (15), although GP3ST prefers N-acetyllactosamine to the O-glycan core 1 structure. Since the sulfation of core 1 prevents the branching reaction to form a core 2 structure (15), GP3ST may regulate the biosynthesis of core 2. GP3ST also acts on methyl-beta -galactoside to some extent, like the mucin 3'-sulfotransferase in human respiratory mucosa (13). Since N-acetyllactosamine is a good substrate for GP3ST, it may catalyze the sulfation of the N-acetyllactosamine structures of N-glycans like the calf thyroid 3'-sulfotransferase (4). The issue of whether GP3ST actually acts on N-glycans, O-glycans, or both remains to be solved.

The reaction product of GP3ST, 3'-sulfo-Galbeta 1-3GlcNAcbeta 1-3Galbeta 1-4Glc, can be an oligosaccharide ligand for L-selectin in vitro (38). Furthermore, the 3'-sulfo-Lea (Galbeta 1-3(Fucalpha 1-4)GlcNAc-R) and -LeX (Galbeta 1-4(Fucalpha 1-3)GlcNAc-R) structures were revealed to be more potent ligands for L-selectin than 3'-sialyl-Lea and -LeX (38, 39), although they have been observed only in epithelia (9-11). Alternatively, the 3'-sulfated oligosaccharide chains on epithelia might be involved in the adhesion of microorganisms such as Helicobacter pylori (40). GP3ST might be involved in the biosynthesis of 3'-sulfo-Lea and -LeX epitopes. In the substrate specificity experiment (Table I), lacto-N-tetraose and lacto-N-neotetraose served as good substrates for the cloned 3'-sulfotransferase, whereas neither lacto-N-fucopentaose II nor lacto-N-fucopentaose III served as a substrate. This result suggests that 3'-sulfation of the nonreducing terminal Gal residue occurs prior to the 3/4-fucosylation of the penultimate GlcNAc residue in the biosynthetic pathway of 3'-sulfo-Lea and -LeX structures, as 3'-sialylation occurs before the 3/4-fucosylation in the synthetic pathway of 3'-sialyl-Lea and -LeX (41, 42).

The expression of the GP3ST gene was found to be ubiquitous, with a relatively high level in the colon, where a considerable amount of mucin is generated and secreted. GP3ST may be involved in the biosynthesis of sulfated mucin in the human colon. A decreased level of mucin sulfation has been observed in colon carcinomas and ulcerative colitis (43-46). This decrease in mucin sulfation is associated with reduced Gal-3'-sulfotransferase activity (14, 47). In some human breast cancer cell lines, the similar sulfotransferase activity is much lower than in normal mammary cells (16). It would be interesting to study the expression of the GP3ST gene in tumor and normal tissues of these secreting organs. The high level of GP3ST expression in heart might be involved in the production of the tumor necrosis factor-alpha -inducible sulfated ligand for L-selectin in human cardiac microvascular endothelial cells (48).

To measure the enzyme activity of a large number of samples, it is essential to establish a simple and sensitive assay method. The method developed in this study does not require radioisotopes and is a convenient and very sensitive assay method for GP3ST using a unique fluorescent-labeled pyridylaminated oligosaccharide as an acceptor substrate. The method is sufficiently sensitive for the detection of 0.5 pmol of reaction product and can be applied to other sulfotransferase assays. In conclusion, we report the cloning of the cDNA of beta -Gal-3'-sulfotransferase that is involved in the biosynthesis of glycoprotein and propose a novel beta -Gal-3'-sulfotransferase gene family.


    ACKNOWLEDGEMENT

We thank Maiko Hashizume for technical assistance.


    FOOTNOTES

* This work was supported by Grant-in-aid 10178104 for Scientific Research on Priority Areas from the Ministry of Education, Science, and Culture of Japan.The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

The nucleotide sequence reported in this paper has been submitted to the DDBJ/GenBankTM/EBI Data Bank with accession number AB040610.

§ To whom correspondence should be addressed: Dept. of Biochemistry, Osaka University Medical School, Rm. B1, 2-2 Yamadaoka, Suita, Osaka 565-0871, Japan. Tel.: 81-6-6879-3421; Fax: 81-6-6879-3429; E-mail: khonke@biochem.med.osaka-u.ac.jp.

Published, JBC Papers in Press, October 11, 2000, DOI 10.1074/jbc.M005666200


    ABBREVIATIONS

The abbreviations used are: PAPS, 5'-phosphoadenosine 3'-phosphosulfate; CST, cerebroside sulfotransferase; Lc4, lacto-N-neotetraose; nLc4, lacto-N-neotetraose; PA, pyridylaminated; RT-PCR, reverse transcription-polymerase chain reaction; RACE, rapid amplification of cDNA ends; MES, 2-(N-morpholino)ethanesulfonic acid; HPLC, high performance liquid chromatography; DQF, double quantum filter; HOHAHA, homonuclear Hartmann-Hahn spectroscopy; ROESY, rotational nuclear overhauser effect spectroscopy; MOPS, 3-(N-morpholino)propanesulfonic acid; PA-Lc4-S, sulfated pyridylaminated lacto-N-neotetraose.


    REFERENCES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES


1. Brockhausen, I., and William, K. (1997) Trends Glycosci. Glycotechnol. 9, 379-398
2. Honke, K., Yamane, M., Ishii, A., Kobayashi, T., and Makita, A. (1996) J. Biochem. (Tokyo) 119, 421-427[Abstract]
3. Honke, K., Tsuda, M., Hirahara, Y., Ishii, A., Makita, A., and Wada, Y. (1997) J. Biol. Chem. 272, 4864-4868[Abstract/Free Full Text]
4. Kato, Y., and Spiro, R. (1989) J. Biol. Chem. 264, 3364-3371[Abstract/Free Full Text]
5. de Waard, P., Koorevaar, A., Kamerling, J., and Vliegenthart, J. (1991) J. Biol. Chem. 266, 4237-4243[Abstract/Free Full Text]
6. Mawhinney, T., Adelstein, E., Morris, D., Mawhinney, A., and Barbergo, G. (1987) J. Biol. Chem. 262, 2994-3001[Abstract/Free Full Text]
7. Strecker, G., Wieruszeski, J., Martel, C., and Montreuil, J. (1987) Glycoconjugate J. 4, 329-337
8. Capon, C., Leory, Y., Wieruszeski, J.-M., Ricart, G., Strecker, G., Montreuil, J., and Fournet, B. (1989) Eur. J. Biochem. 182, 139-152[Abstract]
9. Lamblin, G., Rahmoune, H., Wieruszeski, J., Lhermitte, M., Strecker, G., and Roussel, P. (1991) Biochem. J. 275, 199-206[Medline] [Order article via Infotrieve]
10. Yuen, C., Lawson, A., Chai, W., Larkin, M., Stoll, M., Stuart, A., Sullivan, F., Ahern, T., and Feizi, T. (1992) Biochemistry 31, 9126-9131[Medline] [Order article via Infotrieve]
11. Capon, C., Wieruszeski, J.-M., Lemoine, J., Byrd, J. C., Leffler, H., and Kim, Y. S. (1968) (1997) J. Biol. Chem. 272, 31957-31968[Abstract/Free Full Text]
12. Hokke, C., Damm, J., Penninkhof, B., Aitken, R., Kamerling, J., and Vliegenthart, J. (1994) Eur. J. Biochem. 221, 491-512[Abstract]
13. Lo-Guidice, J., Perini, J., Lafitte, J., Ducourouble, M., Roussel, P., and Lamblin, G. (1995) J. Biol. Chem. 270, 27544-27550[Abstract/Free Full Text]
14. Yang, J., Byrd, J., Siddiki, B., Chung, Y., Okuno, M., Sowa, M., Kim, Y., Matta, K. L., and Brockhausen, I. (1994) Glycobiology 4, 873-884[Abstract]
15. Kuhns, W., Jain, R. K., Matta, K. L., Paulsen, H., Baker, M., Geyer, R., and Brockhausen, I. (1995) Glycobiology 5, 689-697[Abstract]
16. Brockhausen, I., Yang, J., Burchell, J., Whitehouse, C., and Taylor- Papadimitriou, J. (1995) Eur. J. Biochem. 233, 607-617[Abstract]
17. Fukuta, M., Inazawa, J., Torii, T., Tsuzuki, K., Shimada, E., and Habuchi, O. (1997) J. Biol. Chem. 272, 32321-32328[Abstract/Free Full Text]
18. Uchimura, K., Muramatsu, H., Kadomatsu, K., Fan, Q.-W., Kurosawa, N., Mitsuoka, C., Kanngai, R., Habuchi, O., and Muramatsu, T. (1998) J. Biol. Chem. 273, 22577-22583[Abstract/Free Full Text]
19. Bistrup, A., Bhakta, S., Lee, J. K., Belov, Y. C., Gunn, M. D., Zuo, F.-R., Huang, C.-C., Kannagi, R., Rosen, S. D., and Hemmerich, S. (1999) J. Cell Biol. 145, 899-910[Abstract/Free Full Text]
20. Lee, J. K., Bhakta, S., Rosen, S. D., and Hemmerich, S. (1999) Biochem. Biophys. Res. Commun. 263, 543-549[CrossRef][Medline] [Order article via Infotrieve]
21. Frohman, M. A., Dush, M. K., and Martin, G. R. (1988) Proc. Natl. Acad. Sci. U. S. A. 85, 8998-9002[Abstract]
22. Iida-Tanaka, N., and Ishizuka, I. (2000) Carbohydr. Res. 324, 218-222[CrossRef][Medline] [Order article via Infotrieve]
23. Yamamoto, H., Iida-Tanaka, N., Kasama, T., Ishizuka, I., Kushi, Y., and Handa, S. (1999) J. Biochem. (Tokyo) 125, 923-930[Abstract]
24. Kawakami, M., and Nakayama, J. (1997) Cancer Res. 57, 2321-2324[Abstract]
25. Murray, J., Buard, J., Neil, D. L., Yeramian, E., Tamaki, K., Hollies, C., and Jeffreys, A. J. (1999) Genome Res. 9, 130-136[Abstract/Free Full Text]
26. Kakuta, Y., Pedersen, L. G., Pedersen, L. C., and Negishi, M. (1998) Trends Biochem. Sci. 23, 129-130[CrossRef][Medline] [Order article via Infotrieve]
27. Hase, S., Ikenaka, T., and Matsushima, Y. (1978) Biochem. Biophys. Res. Commun. 85, 257-263[Medline] [Order article via Infotrieve]
28. Taniguchi, N., Nishikawa, A., Fujii, S., and Gu, J. (1989) Methods Enzymol. 179, 397-408[Medline] [Order article via Infotrieve]
29. Tadano-Aritomi, K., Kubo, H., Ireland, P., Hikita, T., and Ishizuka, I. (1998) Glycobiology 8, 341-350[Abstract/Free Full Text]
30. Matsubara, T., Iida-Tanaka, N., Kamekura, M., Moldoveanu, N., Ishizuka, I., Onishi, H., Hayashi, A., and Kates, M. (1994) Biochim. Biophys. Acta 1214, 97-108[Medline] [Order article via Infotrieve]
31. Hashimoto, Y., Orellana, A., Gil, G., and Hirschberg, C. B. (1992) J. Biol. Chem. 267, 15744-15750[Abstract/Free Full Text]
32. Orellana, A., Hirschberg, C. B., Wei, Z., Swiedler, S. J., and Ishihara, M. (1994) J. Biol. Chem. 269, 2270-2276[Abstract/Free Full Text]
33. Kusche-Gullberg, M., Ericksson, I., Sandbäck, P., and Kjellén, L. (1998) J. Biol. Chem. 273, 11902-11907[Abstract/Free Full Text]
34. Schworak, N. W., Liu, J., Fritze, L. M. S., Schwartz, J. J., Zhang, L., Logeart, D., and Rosenberg, R. D. (1997) J. Biol. Chem. 272, 28008-28019[Abstract/Free Full Text]
35. Schworak, N. W., Liu, J., Petros, L. M., Zhang, L., Kobayashi, M., Copeland, N. G., Jenkins, N. A., and Rosenberg, R. D. (1999) J. Biol. Chem. 274, 5170-5184[Abstract/Free Full Text]
36. Habuchi, H., Tanaka, M., Habuchi, O., Yoshida, K., Suzuki, H., Ban, K., and Kimata, K. (2000) J. Biol. Chem. 275, 2859-2868[Abstract/Free Full Text]
37. Fukuta, M., Uchimura, K., Nakashima, K., Kato, M., Kimata, K., Shinomura, T., and Habuchi, O. (1995) J. Biol. Chem. 270, 18575-18580[Abstract/Free Full Text]
38. Green, P. J., Tamatani, T., Watanabe, T., Miyasaka, M., Hasegawa, A., Kiso, M., Yuen, C. T., Stoll, M. S., and Feizi, T. (1992) Biochem. Biophys. Res. Commun. 188, 244-251[Medline] [Order article via Infotrieve]
39. Feizi, T., and Galustian, C. (1999) Trends Biochem. Sci. 24, 369-372[CrossRef][Medline] [Order article via Infotrieve]
40. Namavar, F., Sparrius, M., Veerman, E. C., Appelmelk, B. J., and Vandenbroucke-Grauls, C. M. (1998) Infect. Immun. 66, 444-447[Abstract/Free Full Text]
41. Hansson, G. C., and Zopf, D. (1985) J. Biol. Chem. 260, 9388-9392[Abstract/Free Full Text]
42. Holmes, E. H., Ostrander, G. K., and Hakomori, S. (1986) J. Biol. Chem. 261, 3737-3743[Abstract/Free Full Text]
43. Filipe, M. (1969) Gut 10, 577-586[Medline] [Order article via Infotrieve]
44. Yamori, T., Kimura, H., Stewart, K., Ota, D. M., Cleary, K. R., and Irimura, T. (1987) Cancer Res. 47, 2741-2747[Abstract]
45. Raouf, A. H., Tsai, H. H., Parker, N., Hoffman, J., Walker, R. J., and Rhodes, M. (1992) Clin. Sci. (Lond.) 83, 623-626[Medline] [Order article via Infotrieve]
46. Irimura, T., Wynn, D. M., Hager, L. G., Cleary, K. R., and Ota, D. M. (1991) Cancer Res. 51, 5728-5735[Abstract]
47. Vavasseur, F., Dole, K., Yang, J., Matta, K. L., Myerscough, N., Cornfield, A., Paraskeva, C., and Brockhausen, I. (1994) Eur. J. Biochem. 222, 415-424[Abstract]
48. Zakrzewicz, A., Grafe, M., Terbeek, D., Bongrazio, M., Auch-Schwelk, W., Walzog, B., Graf, K., Fleck, E., Ley, K., and Gaehtgens, P. (1997) Blood 89, 3228-3235[Abstract/Free Full Text]


Copyright © 2001 by The American Society for Biochemistry and Molecular Biology, Inc.